Vivoryon Therapeutics N.V. (AMS:VVY)

Netherlands flag Netherlands · Delayed Price · Currency is EUR
1.682
-0.018 (-1.06%)
Jun 5, 2025, 4:06 PM CET
-40.77%
Market Cap 44.05M
Revenue (ttm) n/a
Net Income (ttm) -20.57M
Shares Out 26.07M
EPS (ttm) -0.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 45,436
Average Volume 54,741
Open 1.700
Previous Close 1.700
Day's Range 1.676 - 1.700
52-Week Range 1.320 - 3.060
Beta 1.98
RSI 37.22
Earnings Date Sep 9, 2025

About Vivoryon Therapeutics

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 14
Stock Exchange Euronext Amsterdam
Ticker Symbol VVY
Full Company Profile

Financial Performance

Financial Statements

News

Vivoryon Therapeutics NV (STU:05Y) Q3 2024 Earnings Call Highlights: Strategic Shifts and ...

Vivoryon Therapeutics NV (STU:05Y) Q3 2024 Earnings Call Highlights: Strategic Shifts and Financial Challenges

6 months ago - GuruFocus

Q3 2024 Vivoryon Therapeutics NV Earnings Call Transcript

Q3 2024 Vivoryon Therapeutics NV Earnings Call Transcript

6 months ago - GuruFocus